Kathryn de Santis
Investor Relations Contact chez Sucampo Pharma Americas, Inc.
Profil
Kathryn de Santis is currently the VP-Investor Relations & Corporate Communications at Sucampo Pharma Americas, Inc. She previously held the same position at Sucampo Pharmaceuticals, Inc. and was the Director-Corporate Communications at Human Genome Sciences, Inc. She received an undergraduate degree from Molloy College and an MBA from Pace University.
Postes actifs de Kathryn de Santis
| Sociétés | Poste | Début |
|---|---|---|
| Sucampo Pharma Americas, Inc. | Investor Relations Contact | - |
Anciens postes connus de Kathryn de Santis
| Sociétés | Poste | Fin |
|---|---|---|
| SUCAMPO PHARMACEUTICALS, INC. | Investor Relations Contact | 29/06/2012 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Public Communications Contact | - |
Formation de Kathryn de Santis
| Pace University | Masters Business Admin |
| Molloy College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Sucampo Pharmaceuticals, Inc.
 Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
| Sucampo Pharma Americas, Inc. |
